Clinical Trial: Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer

U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07059949) titled 'Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer' on April 17.

Brief Summary: To evaluate the efficacy and safety of short-course radiotherapy followed by CAPOX and carrilizumab and bevacizumab or cetuximab in the initial treatment of unresectable metastatic rectal cancer

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Unresectable Metastatic Rectal Cancer CAPOX Combination of Radioimmunotherapy

Intervention: DRUG: CAPOX+ Camrelizumab+ Cetuximab

For advanced primary treatment of unresectable rectal cance...